BiomX Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 71

Employees

  • Stock Symbol
  • PHGE

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.61
  • (As of Friday Closing)

BiomX General Information

Description

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Contact Information

Website
www.biomx.com
Formerly Known As
MBcure
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 708 Quince Orchard Road
  • Suite 205
  • Gaithersburg, MD 20878
  • United States
+1 (844)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ASE
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 708 Quince Orchard Road
  • Suite 205
  • Gaithersburg, MD 20878
  • United States
+1 (844)

BiomX Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BiomX Stock Performance

As of 25-Apr-2025, BiomX’s stock price is $0.61. Its current market cap is $15.2M with 25M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.61 $0.61 $0.48 - $4.99 $15.2M 25M 117K -$1.47

BiomX Financials Summary

As of 31-Dec-2024, BiomX has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 18,126 18,126 6,632 (15,612)
Revenue 0 0 0 0
EBITDA (16,086) (16,086) (23,993) (24,127)
Net Income (17,727) (17,727) (26,169) (28,317)
Total Assets 43,233 43,233 25,029 45,531
Total Debt 9,584 9,584 15,092 19,358
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BiomX Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BiomX‘s full profile, request access.

Request a free trial

BiomX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to t
Biotechnology
Gaithersburg, MD
71 As of 2023

Aberdeen, United Kingdom
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BiomX Competitors (36)

One of BiomX’s 36 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Xeno Biosciences Venture Capital-Backed Cambridge, MA
PEP-Therapy Venture Capital-Backed Evry Cedex, France
SynDevRx Venture Capital-Backed Cambridge, MA
Eligo Bioscience Venture Capital-Backed Paris, France
You’re viewing 5 of 36 competitors. Get the full list »

BiomX Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 21

    Pending

  • Expiring in next 12 mo

BiomX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3218291-A1 Staphylococcus bacteriophage and uses thereof Pending 12-May-2021
AU-2022272135-A1 Staphylococcus bacteriophage and uses thereof Pending 12-May-2021
EP-4337764-A1 Staphylococcus bacteriophage and uses thereof Pending 12-May-2021
US-20240415904-A1 Staphylococcus bacteriophage and uses thereof Pending 12-May-2021
AU-2022247325-A1 Pseudomonas bacteriophage and uses thereof Pending 30-Mar-2021 A61K35/76
To view BiomX’s complete patent history, request access »

BiomX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BiomX Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BiomX‘s full profile, request access.

Request a free trial

BiomX Acquisitions (3)

BiomX’s most recent deal was a Merger/Acquisition with Adaptive Phage Therapeutics for . The deal was made on 15-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Adaptive Phage Therapeutics 15-Mar-2024 Merger/Acquisition Drug Discovery
Chardan Healthcare Acquisition 28-Oct-2019 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
RondinX 19-Dec-2017 Merger/Acquisition Drug Discovery
To view BiomX’s complete acquisitions history, request access »

BiomX FAQs

  • When was BiomX founded?

    BiomX was founded in 2015.

  • Where is BiomX headquartered?

    BiomX is headquartered in Gaithersburg, MD.

  • What is the size of BiomX?

    BiomX has 71 total employees.

  • What industry is BiomX in?

    BiomX’s primary industry is Biotechnology.

  • Is BiomX a private or public company?

    BiomX is a Public company.

  • What is BiomX’s stock symbol?

    The ticker symbol for BiomX is PHGE.

  • What is the current stock price of BiomX?

    As of 25-Apr-2025 the stock price of BiomX is $0.61.

  • What is the current market cap of BiomX?

    The current market capitalization of BiomX is $15.2M.

  • Who are BiomX’s competitors?

    NovaBiotics, Xeno Biosciences, PEP-Therapy, SynDevRx, and Eligo Bioscience are some of the 36 competitors of BiomX.

  • What is BiomX’s annual earnings per share (EPS)?

    BiomX’s EPS for 12 months was -$1.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »